News
Novo Nordisk Names Maziar Mike Doustdar as President and Chief Executive Officer
Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief executive officer (CEO). Jørgensen will step down from his current role serving as president and CEO on the same day Doustdar is expected to take over.
The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...
Professor Lene Oddershede Chief Scientific Officer, Planetary Science & Technology at the Novo Nordisk Foundation talks about the applications of quantum computing at the tech disruptors podcast. She ...
The Novo Nordisk Foundation, top shareholder of Danish obesity drugmaker Novo Nordisk, plans to give a larger portion of its social, scientific and humanitarian grants outside of Denmark, a ...
LONDON (Reuters) - The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded foreign aid, and will continue to focus on its core ...
The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
In a release on Tuesday, Novo Nordisk cut its expected full-year sales growth to 8%-14%, down from the 13%-21% it had ...
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback